Clinical trials: Sleep Disturbances and Insomnia
Post-Concussion Symptoms, Insomnia
Neurotechnology Following Traumatic Brain Injury
This two-part study seeks to improve symptoms such as pain and sleep problems after concussion, or mild traumatic brain injury (mTBI).
- Conditions
- Post-Concussion Symptoms, Insomnia, Pain, Chronic, Depressive Symptoms
- Trial name
- Cereset (NCT03649958)
- Testing
- HIRREM-SOP or Cereset, Cereset 2x
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Brain State Technologies, LLC
CNS
2-Part Multiple Ascending Dose Study for Safety and Pharmacokinetics in Healthy and Elderly Subjects
This is a single-center, randomized, double-blind, placebo-controlled, sequential, multiple-dose study. The study will be conducted in two parts: Part A (6 cohorts of healthy adults receiving evening dosing) and Part B (one…
- Trial name
- NCT01673451
- Testing
- E2006
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Insomnia Disorder
Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep
Study to assess the long term safety and tolerability of daridorexant in adult and elderly subjects suffering from difficulties to sleep
- Trial name
- NCT03679884
- Testing
- Daridorexant 10 mg, Daridorexant 25 mg, Daridorexant 50 mg
- Where
- 106 sites in United States, Belgium and 12 more
- Volunteers
- 804 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Insomnia, Hepatic Impairment
Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Mild, Moderate and Normal Hepatic Impairment
Primary Objectives: To evaluate the effect of the subjects with mild (Child Pugh A), moderate (Child Pugh B) and normal hepatic impairment on the pharmacokinetics of YZJ-1139 Secondary Objectives: To evaluate the safety of a…
- Trial name
- NCT06671509
- Testing
- YZJ-1139
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Sleep Initiation and Maintenance Disorders
A Study of Lemborexant in Chinese Participants With Insomnia Disorder
The primary purpose of this study is to confirm using polysomnography (PSG) that lemborexant 10 milligram (mg) is superior to placebo on objective sleep onset as assessed by latency to persistent sleep (LPS) during the last 2…
- Trial name
- NCT04549168
- Testing
- Lemborexant
- Where
- 23 sites in China, Taiwan
- Volunteers
- 194 people
- Sponsor
- Eisai Co., Ltd.
Primary Insomnia
Adult Polysomnography Primary Insomnia Cross Over Study (0928-049)(TERMINATED)
The purpose of this study is determine whether this drug will improve your insomnia in terms of decreasing your time to fall asleep and allowing you to stay asleep longer.
- Trial name
- NCT00420810
- Testing
- MK0928 / Duration of Treatment : 8 Weeks
- Volunteers
- 138 people
- Sponsor
- H. Lundbeck A/S
Sleep Quality, Sleep Health
Clinical Study to Assess a Dietary Supplement on Sleep Health and Quality
The primary objective of this study is to evaluate the effects of a proprietary oral supplement on the sleep health and quality of people with sleep problems. It is a double-blinded placebo-controlled crossover clinical study.
- Trial name
- NCT05368909
- Testing
- Sleep Supplement
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- 4Life Research, LLC
Sleep Initiation and Maintenance Disorders
Radiolabel Study In Healthy Volunteers For Insomnia-Targeting Drug
The purpose of this study is to define the absorption, breakdown and excretion of a single dose of radiolabelled SB-649868 and its breakdown products by measuring their concentration in blood, urine and faeces over a 7-10 day…
- Trial name
- NCT00520663
- Testing
- 14C-SB649868
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Insomnia Disorder
A Study of HS-10506 in Chinese Patients With Insomnia Disorder
The primary purpose of this phase 3 study is to evaluate the safety and the efficacy of HS-10506 (change versus placebo) on latency to persistent sleep (LPS) and wakefulness after sleep onset (WASO) measured by polysomnography…
- Trial name
- NCT07587385
- Testing
- HS-10506
- Volunteers
- 732 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Sleep Initiation and Maintenance Disorders
Efficacy and Safety of KI1001 in ≥ 55 Years Old Insomnia Patients
KI1001(Circadin®, Prolonged release tablet which contains melatonin) has showed its efficacy to improve sleep quality in over 55 years old primary insomnia patients.
- Trial name
- NCT01450228
- Testing
- KI1001
- Where
- 10 sites in South Korea
- Volunteers
- 170 people
- Sponsor
- Kuhnil Pharmaceutical Co., Ltd.
Mood, Cognitive Performance
The Effects of A Proprietary Spearmint Extract on Cognitive Performance
This study was designed to evaluate the chronic effects of a proprietary spearmint extract over 90 days of supplementation on aspects of cognitive performance (cognitive function and active reaction time), subjective mood, and…
- Conditions
- Mood, Cognitive Performance, Sleep
- Trial name
- NCT02518165
- Testing
- Proprietary spearmint extract
- Where
- United States
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Kemin Foods LC
Insomnia
A Dose-Ranging, Multicenter Polysomnography Trial of PD 0200390 in Elderly Subjects With Primary Insomnia
This is a randomized, double-blind, placebo-controlled, multicenter trial with a 4-way crossover design. Elderly subjects with primary insomnia who meet screening requirements will initially be randomized into the study and…
- Trial name
- NCT00748592
- Testing
- PD 0200390
- Sponsor
- Pfizer
Insomnia
Pharmacokinetics of Suvorexant in Participants With Impaired Renal Function (MK-4305-023)(COMPLETED)
This study will investigate whether the plasma concentration-time profile and pharmacokinetics (PK) of suvorexant (MK-4305) in participants with impaired renal function are similar to those observed in healthy participants; and…
- Trial name
- NCT01059851
- Testing
- Suvorexant
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Insomnia, Stress
Evaluation of the Effects of Saffron Extract on Sleep Quality and Stress
Therefore, the aim of this study was to confirm by a randomized double-blind controlled study the beneficial effects of saffron extract (Saffr'activ®) on sleep quality in subjects presenting mild to moderate sleep disorder…
- Trial name
- NCT04750681
- Testing
- Saffron
- Where
- Belgium
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Comercial Quimica Masso, S.A
Chronic Primary Insomnia
Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia
A 2-night polysomnography / 5-way cross-over study to evaluate the effect, safety and tolerability of oral administration of almorexant (ACT 078573) in elderly subjects with primary insomnia.
- Trial name
- NCT00606593
- Where
- 21 sites in United States
- Volunteers
- 112 people
- Sponsor
- Midnight Pharma, LLC
Insomnia
Study of MK0928 in Healthy Adult Volunteers in a Model of Insomnia (0928-006)(COMPLETED)
A study to evaluate the safety and effectiveness of Study of MK0928 in Healthy Adult Volunteers in a Model of Insomnia for insomnia (a sleep disorder).
- Trial name
- NCT00102167
- Testing
- gaboxadol
- Volunteers
- 663 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Sleep Initiation and Maintenance Disorders, Insomnia
Effects Of GW679769 On Sleep Onset And Maintenance,And Next Day Functioning In The Elderly And Non-elderly With Primary Insomnia
This study is designed to find the optimal (best) doses of GW679769 that promote sleep onset and maintain sleep during two consecutive nights of dosing without significant next-day thinking impairment and drowsiness in subjects…
- Trial name
- NCT00280436
- Testing
- GW679769
- Where
- 26 sites in United States
- Volunteers
- 122 people
- Sponsor
- GlaxoSmithKline
Primary Insomnia
Polysomnography Study of MK-6096 in Participants With Primary Insomnia (MK-6096-011)
This was a cross-over, polysomnography (PSG) study to test the safety, tolerability and effectiveness of different doses of MK-6096 in the treatment of participants with primary insomnia.
- Trial name
- NCT01021852
- Testing
- MK-6096
- Volunteers
- 326 people
- Sponsor
- Merck Sharp & Dohme LLC
Insomnia, Breast Cancer
PERSONAL - Sleep In Breast Cancer
Sleep is essential for human function, immunity, and well-being. In the general population, sleep disturbance and insomnia cause significant health problems and impact on the quality of life of many individuals.
- Trial name
- NCT05093426
- Testing
- Stage 2 Digital sleep diary app
- Where
- United Kingdom
- Volunteers
- 226 people
- Sponsor
- Closed Loop Medicine
Sleep Quality
Comparison of Four Qualia Sleep Formulations on Sleep Quality : An Open-label 4-arm Pilot Study
This is a randomized, open-label, 4-arm pilot study designed to evaluate the efficacy and tolerability of four Qualia Sleep formulations (Formulas A, B, C, and D) in healthy adults aged 18 years and older who report poor sleep…
- Trial name
- NCT07744971
- Testing
- Qualia Sleep Formula A, Qualia Sleep Formula B, Qualia Sleep Formula C
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Qualia Life Sciences